A strategic approach to COVID-19 vaccine R&D

Science. 2020 May 29;368(6494):948-950. doi: 10.1126/science.abc5312. Epub 2020 May 11.

Authors

Lawrence Corey^{1

2}, John R Mascola³, Anthony S Fauci⁴, Francis S Collins⁵

Affiliations

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
² Departments of Medicine and Lab Medicine, University of Washington, Seattle, WA 98195, USA.
³ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
⁴ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. afauci@niaid.nih.gov.
⁵ National Institutes of Health, Bethesda, MD 20892, USA.

PMID: 32393526
DOI: 10.1126/science.abc5312

No abstract available

MeSH terms

Adjuvants, Immunologic
Animals
Betacoronavirus / immunology*
COVID-19
COVID-19 Vaccines
Clinical Trial Protocols as Topic
Clinical Trials as Topic
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Disease Models, Animal
Humans
Immunogenicity, Vaccine
International Cooperation
National Institutes of Health (U.S.)
Pandemics / prevention & control*
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Public-Private Sector Partnerships*
RNA, Messenger
SARS-CoV-2
Spike Glycoprotein, Coronavirus / immunology
T-Lymphocytes / immunology
United States
Vaccines, DNA
Vaccines, Synthetic / immunology
Viral Vaccines* / adverse effects
Viral Vaccines* / immunology

Substances

Adjuvants, Immunologic
COVID-19 Vaccines
RNA, Messenger
Spike Glycoprotein, Coronavirus
Vaccines, DNA
Vaccines, Synthetic
Viral Vaccines
spike protein, SARS-CoV-2